// App-Quantinova.ai

9574 : Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.

Researchers

Presenter

  • Jeffrey S. Weber

Principal Investigators

  • Helen Gogas

  • Xiaowu Sun

  • Christine Yip

  • Fiona Taylor

  • Julia Braverman

  • Maurice Lobo

  • Pratik K. Thakkar

  • Andriy Moshyk

  • James Larkin

  • Paolo Antonio Ascierto

Medical Centers

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, National and Kapodistrian University of Athens, Athens, Greece

  • Adelphi Values, Boston, MA

  • Bristol Myers Squibb, Princeton, NJ, Bristol Myers Squibb, Uxbridge, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

Locations

  • Greece

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02388906

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved